

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.
Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK ROAD,
JAIPUR - 302015 (Rajasthan)
CIN: L85110RJ1989PLC005206

04.11.2022
Jaipur

To,
The Manager,
Corporate Relationship Department,
BSE Ltd.
25th Floor P.J. Towers,
Dalal Street, Fort,
MUMBAI-400 001.

Ref: Scrip Code: - 524548

Sub: Outcome of Board Meeting held on Friday 04.11.2022 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the 2022-23/04 Meeting of Board of Directors of the Company held on Friday 04th November, 2022, the meeting was started at 03.00 P.M. and concluded at 08:15 P.M.

Approved Unaudited Financial Results for the 2nd quarter/01st half year ended on 30th September, 2022 of the Financial Year 2022-23 and noted Limited Review Report on the same (Copy enclosed).

Kindly take it on record and acknowledge the same.

Thanking You,

Yours faithfully
For SHARMA EAST INDIA HOSPITALS &
MEDICAL RESEARCH LIMITED


Bhawana Sharma
(Company Secretary
And Compliance Officer)
M.No. A61665



Contact: 0141-2742266 / 2742619
Fax: 0141-2742472

E-mail - sharmaeastindia@gmail.com
Website: www.jaipurhospital.co.in



Independent Auditor's Limited Review Report on unaudited Half-Yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors
Sharma East India Hospitals & Medical Research Ltd

1. We have reviewed the accompanying Statement of Un-audited Financial Results of Sharma East India Hospitals & Medical Research Limited (the "company") for the quarter and half year ended on 30th September 2022 being submitted by the company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR GOPAL SHARMA & CO.
CHARTERED ACCOUNTANTS

GAUTAM SHARMA Digitally signed by
GAUTAM SHARMA
Date: 2022.11.04
20:13:56 +05'30'

(CA GAUTAM SHARMA)
PARTNER

Membership No. 079225
Firm Registration No. 002803C

UDIN : 22079225BCCYKG8091

Jaipur
November 04, 2022

STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPT. 2022

Rs. In Lakhs

PARTICULARS	For the Half year ended Sept. 30, 2022	For the year ended March 31, 2022
A. Cash Flow from Operating Activities		
Profit before tax	35.08	83.22
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation and Impairment of property, plant and equipment	57.58	78.01
(Gain)/Loss on disposal of property, plant and equipment	-	-
Interest income	-	(0.59)
Finance costs	52.57	70.22
Incremental Interest	-	-
Movements in provisions	(4.18)	(0.07)
Other adjustments to reconcile profit or loss	-	-
Operating Profit before working capital changes	141.05	230.79
Working Capital Changes:		
Increase/(Decrease) in non current assets	(19.92)	-
Increase/(Decrease) in other financial assets	(7.11)	-
Increase/(Decrease) in non current liabilities	-	(34.00)
(Increase)/Decrease in trade and other receivables and prepayments	(40.86)	(70.94)
(Increase)/Decrease in other assets & liabilities	-	93.63
(Increase)/Decrease in other current assets	(598.25)	(104.15)
(Increase)/Decrease in inventories	(20.17)	10.42
Increase/(Decrease) in other current financial liabilities	(33.01)	(20.98)
Increase/(Decrease) in other current liabilities	17.51	56.54
Increase/(Decrease) in trade and other payables	82.58	55.56
Cash Generated from Operations	(478.18)	216.87
Income tax paid	(8.81)	(13.89)
Net Cash from Operating Activities (A)	(486.99)	202.98
B. Cash Flow from Investing Activities		
Proceeds from sale of property, plant and equipment	-	-
Purchase of property, plant and equipment (including Capital Work in Progress)	(275.43)	(211.73)
Interest received	-	0.59
Net Cash used in Investing Activities(B)	(275.43)	(211.14)
C. Cash Flow from Financing Activities		
Proceeds from / (Repayment of) Short Term Borrowings	770.91	(131.69)
Proceeds from / (Repayment of) Long Term Borrowings	46.13	23.94
Interest Paid	(52.57)	(70.22)
Net cash used in Financing Activities (C)	764.47	(177.97)
Net Increase/(Decrease) in cash and cash equivalents(A+B+C)	2.05	(186.13)
Cash and cash equivalents at the beginning of the year	27.23	213.36
Cash and cash equivalents at the end of the year	29.28	27.23



SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED
NEAR SMS STADIUM, LAL KOTHI, TONK ROAD
JAIPUR
CIN: L85110RJ1989PLC005206

Statement of Standalone Unaudited Financial Results for the Quarter/Half Year Ended 30th Sept. 2022

(Rs. in lakhs)

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)	30.09.2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations						
(a)	Revenue from Operations	510.98	509.40	447.80	1,020.38	712.92	1,703.81
(b)	Other Income	-	-	-	-	-	5.91
	Total Revenue	510.98	509.40	447.80	1,020.38	712.92	1,709.72
2	Expenses						
(a)	Cost of materials consumed	92.95	111.91	90.53	204.86	129.15	343.13
(b)	Purchase of stock in trade	6.28	9.23	0.57	15.51	1.18	4.69
(c)	Change in Inventories of stock in trade	0.00	-	-	-	-	(1.58)
(d)	Employee benefits expense	55.41	52.82	54.97	108.23	110.92	188.40
(e)	Finance cost	26.40	26.17	17.93	52.57	37.56	70.22
(f)	Depreciation and amortisation expense	35.45	22.13	14.76	57.58	29.43	78.01
(g)	Other Expenses	277.40	269.15	241.48	546.55	365.04	943.63
	Total Expenses	493.89	491.41	420.24	985.30	673.28	1,626.50
3	Profit/(Loss) before exceptional items & tax (1-2)	17.09	17.99	27.56	35.08	39.64	83.22
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax (3-4)	17.09	17.99	27.56	35.08	39.64	83.22
6	Tax expense						
	Current tax	8.80	-	10.31	8.80	10.31	12.98
	Taxation for Earlier year	-	-	-	-	-	0.91
	Deferred tax	0.32	-	-	0.32	-	1.32
		9.12	-	10.31	9.12	10.31	15.21
7	Profit/(Loss) for the period (5-6)	7.97	17.99	17.25	25.96	29.33	68.01
8	Other Comprehensive Income						
(i)	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other Comprehensive Income for the period	-	-	-	-	-	-
9	Total Comprehensive Income (7+8)	7.97	17.99	17.25	25.96	29.33	68.01
10	Paid up equity share capital (face value of Rs. 10/- each)	328.38	328.38	328.38	328.38	328.38	328.38
11	Earning per share						
	Basic	0.24	0.55	0.53	0.79	0.89	2.07
	Diluted	0.24	0.55	0.53	0.79	0.89	2.07

- Notes:
- These results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 04.11.2022. Limited Review Report on the above financial results has been received from the Statutory Auditors of the Company.
 - The figure of previous period/year have been re-grouped/re-arranged and / or recast wherever found necessary.

Place : Jaipur
Date : 04.11.2022

For and on behalf of the Board of Directors
SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED

Shalendra Kumar Sharma
MANAGING DIRECTOR
DIN 00432070



SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED
NEAR SMS STADIUM, TONK ROAD
JAIPUR
CIN: L85110RJ1989PLC005206

STATEMENT OF UNAUDITED ASSETS AND LIABILITIES AS AT SEPTEMBER 30 2022

(Rs. in lakhs)

Particulars	As at 30th September 2022	As at 31st March 2022
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	902.43	684.58
(b) Capital work-in-progress	-	-
(c) Right of use assets	-	-
(d) Intangible Assets	-	-
(e) Financial Assets		
(i) Investments	189.23	189.23
(ii) Others	15.56	14.56
(f) Deferred Tax Assets (Net)	-	-
(g) Other Non-Current Assets	35.70	15.78
Total Non- Current Assets	1,142.92	904.15
Current Assets		
(a) Inventories	66.03	45.86
(b) Financial Assets		
(i) Trade Receivable	379.75	338.90
(ii) Cash and Cash Equivalents	29.28	27.23
(iii) Bank balances other than (iv) above	19.41	19.40
(iv) Others	14.57	8.46
(b) Other Current Assets	1,160.14	561.89
(c) Current Tax Assets (Net)	-	-
Total Current Assets	1,669.18	1,001.74
Total Assets	2,812.10	1,905.89
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	415.75	415.75
(b) Other Equity	569.82	543.86
Total Equity	985.57	959.61
LIABILITIES		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	204.02	157.89
(ii) Lease Liability	-	-
(iii) Other Financial Liabilities	-	-
(b) Deferred Tax Liability	26.14	25.83
(c) Other Non Current Liabilities	-	-
Total Non - current liabilities	230.16	183.72
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,048.23	277.32
(ii) Trade Payables	262.27	179.69
(iii) Lease Liability	-	-
(iv) Other Financial Liabilities	176.75	209.76
(b) Other Current Liabilities	100.31	82.81
(c) Provisions	8.81	12.98
Total Current liabilities	1,596.37	762.56
Total Liabilities	1,826.53	946.28
Total Equity and Liabilities	2,812.10	1,905.89

